Organ preservation trials for laryngeal cancer (Q35066525)

6 August 2017

1 reference

title

Organ preservation trials for laryngeal cancer (English)

1 reference

6 August 2017

0 references

Arlene A Forastiere

1 reference

6 August 2017

Jill Gilbert

1 reference

6 August 2017

publication date

1 October 2002

1 reference

Otolaryngologic Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

1035-54, vi

1 reference

Quality of life after surgical treatment of cancer of the larynx.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Results of radical radiotherapeutic treatment of carcinoma of the pyriform sinus: experience of the Institut Curie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

MR findings of cartilage invasion by laryngeal cancer: value in predicting outcome of radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

The place of radiotherapy in the management of the squamous cell carcinoma of the supraglottic larynx

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

T4nomo glottic cancer: A analysis of dose-time volume factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Deep spread patterns in CT staging of T2-4 squamous cell laryngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Can pretreatment computed tomography predict local control in T3 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

T4 laryngeal carcinoma: Radiotherapy alone with surgery reserved for salvage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Induction chemotherapy in head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Molecular mechanisms of radiation-induced accelerated repopulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

The mechanisms of acceleration of repopulation in squamous epithelia during daily irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Concurrent chemoradiation in the treatment of head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Toxicity in head and neck cancer: a review of trends and issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Hydroxyurea and radiotherapy in head and neck cancer. Results of a prospective controlled study in 126 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: a phase III clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

The epidermal growth factor receptor and its inhibition in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Downmodulation of TGF-α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2802%2900035-X

10.1016/S0030-6665(02)00035-X

7 January 2021

Identifiers

DOI

1 reference

release_7chsmqqjzbatfe4zbm65ni3zaq

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7chsmqqjzbatfe4zbm65ni3zaq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference